Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Quarterly Sales of $57.44 Million
Analysts expect that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will report $57.44 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. The lowest sales estimate is $56.61 million and the highest is $58.60 million. Sucampo Pharmaceuticals reported sales of $57.87 million in the same quarter last year, which indicates a negative year over year growth rate of 0.7%. The business is scheduled to announce its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year sales of $57.44 million for the current fiscal year, with estimates ranging from $228.00 million to $236.90 million. For the next financial year, analysts forecast that the firm will post sales of $243.33 million per share, with estimates ranging from $234.39 million to $258.60 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Sucampo Pharmaceuticals.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The firm had revenue of $59.90 million for the quarter, compared to analyst estimates of $56.44 million. During the same period last year, the firm posted $0.24 EPS. Sucampo Pharmaceuticals’s quarterly revenue was up 15.3% on a year-over-year basis.
Several brokerages have weighed in on SCMP. BidaskClub lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. TheStreet lowered Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $17.63.
TRADEMARK VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Quarterly Sales of $57.44 Million” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/09/11/sucampo-pharmaceuticals-inc-scmp-expected-to-post-quarterly-sales-of-57-44-million.html.
In related news, insider Jones W. Bryan bought 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The stock was acquired at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the acquisition, the insider now directly owns 4,700 shares in the company, valued at approximately $49,820. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jason Patrick Meyenburg bought 4,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Wednesday, September 6th. The shares were bought at an average cost of $12.13 per share, with a total value of $48,520.00. Following the completion of the acquisition, the insider now owns 30,228 shares of the company’s stock, valued at $366,665.64. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in SCMP. Dynamic Technology Lab Private Ltd purchased a new stake in Sucampo Pharmaceuticals in the 2nd quarter worth about $132,000. Public Employees Retirement System of Ohio lifted its stake in Sucampo Pharmaceuticals by 37.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 46,222 shares of the biopharmaceutical company’s stock worth $485,000 after acquiring an additional 12,663 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Sucampo Pharmaceuticals by 4.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 790 shares in the last quarter. State Street Corp lifted its stake in Sucampo Pharmaceuticals by 7.3% in the 2nd quarter. State Street Corp now owns 599,420 shares of the biopharmaceutical company’s stock worth $6,290,000 after acquiring an additional 40,929 shares in the last quarter. Finally, Dana Investment Advisors Inc. lifted its stake in Sucampo Pharmaceuticals by 17.0% in the 2nd quarter. Dana Investment Advisors Inc. now owns 187,449 shares of the biopharmaceutical company’s stock worth $1,968,000 after acquiring an additional 27,294 shares in the last quarter. 55.44% of the stock is owned by institutional investors and hedge funds.
Sucampo Pharmaceuticals (SCMP) opened at 12.35 on Monday. The stock’s market capitalization is $572.11 million. The company has a 50-day moving average of $11.01 and a 200-day moving average of $10.67. Sucampo Pharmaceuticals has a 52-week low of $9.30 and a 52-week high of $17.55.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.